In 2016, two new drugs were introduced on the market in the field of rhythmology, namely Praxbind© and Brivaness©, with their indication revued and commented in this paper. In addition, the European Society of Cardiology published new guidelines. This article sought to review the guidelines' key points regarding dyslipidemia, atrial fibrillation, heart failure, and cardiovascular prevention.
Key words
Praxbind©, Brivaness©, dyslipidemia, atrial fibrillation, heart failure, cardiovascular prévention